Social Media Monitoring Report on Yescarta, a drug by Gilead Sciences, Inc. for relapsed or refractory B-cell lymphoma
Research Study Background
Gilead Sciences, Inc. developed drug Yescarta (axicabtagene ciloleucel) has got US FDA marketing approval on 18th Oct 2017 for adult patients with relapsed or refractory large B-cell lymphoma. Yescarta US FDA approval was based on data from the ZUMA-1 pivotal trial where Yescarta showed significant improvement with complete response rate by 51 % adult patients with relapsed or refractory large B-cell lymphoma. Yescarta represents the second new advance chemotherapy after Kymriah for adult non-Hodgkin lymphoma patients. Gilead Sciences, Inc. got Prior marketing authorization for Yescarta under Priority Review Scheme by FDA.
Sentiment Analysis on Yescarta Drug Approval
Positive: Yescarta approval was quoted as a landmark breakthrough - “Yescarta approval is a landmark. Immunotherapy and gene therapy are the most exciting breakthroughs and future of medicine”- Unidentified individual
Negative: Some were found concerned about Yescarta pricing and reflected negatively on social media channels - “Shame..Yescarta List price ($373k) is higher than median home cost in 46 states.”- Unidentified individual
Neutral: Majority of healthcare practitioners were either neutral or positive about the approval and found sharing the information on social media - “FDA approves CAR-T cell therapy (axicabtagene) for adults with R/R DLBCL.“- HCP